Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vilgelm, A.
Right arrow Articles by Di Cristofano, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vilgelm, A.
Right arrow Articles by Di Cristofano, A.
[Cancer Research 66, 3375-3380, April 1, 2006]
© 2006 American Association for Cancer Research


Priority Reports

Akt-Mediated Phosphorylation and Activation of Estrogen Receptor {alpha} Is Required for Endometrial Neoplastic Transformation in Pten+/– Mice

Anna Vilgelm1, Zenglin Lian1, Hong Wang3, Stephen L. Beauparlant1, Andres Klein-Szanto2, Lora Hedrick Ellenson3 and Antonio Di Cristofano1

1 Human Genetics Program and 2 Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania and 3 Weill Medical College of Cornell University, New York, New York

Requests for reprints: Antonio Di Cristofano, Human Genetics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Phone: 215-214-1647; Fax: 215-214-1623; E-mail: antonio.dicristofano{at}fccc.edu.

PTEN is a tumor suppressor gene frequently mutated in human cancers. In vitro and in vivo studies have shown that PTEN can exert its tumor suppressive function through a variety of mechanisms, including regulation of cell death and cell proliferation. However, it is still unclear which of the many downstream pathways are critical in each different tissue, in vivo. Loss of PTEN is the earliest detectable genetic lesion in the estrogen-related type I (endometrioid) endometrial cancer. Pten+/– mice develop endometrial neoplastic lesions with full penetrance, thus providing a model system to dissect the genetic and biochemical events leading to the transition from normal to hyperplastic and neoplastic endometrial epithelium. Here, we show that loss of Pten in the mouse endometrium activates Akt and results in increased phosphorylation of estrogen receptor {alpha} (ER{alpha}) on Ser167. ER{alpha} phosphorylation results, in turn, in the activation of this nuclear receptor both in vivo and in vitro, even in the absence of ligand, and in its increased ability to activate the transcription of several of its target genes. Strikingly, reduction of endometrial ER{alpha} levels and activity dramatically reduces the neoplastic effect of Pten loss in the endometrium, in contrast to complete estrogen depletion. Thus, we provide for the first time in vivo evidence supporting the hypothesis that loss of Pten and subsequent Akt activation result in the activation of ER{alpha}-dependent pathways that play a pivotal role in the neoplastic process. (Cancer Res 2006; 66(7): 3375-80)




This article has been cited by other articles:


Home page
Cancer Res.Home page
C. M. Contreras, S. Gurumurthy, J. M. Haynie, L. J. Shirley, E. A. Akbay, S. N. Wingo, J. O. Schorge, R. R. Broaddus, K.-K. Wong, N. Bardeesy, et al.
Loss of Lkb1 Provokes Highly Invasive Endometrial Adenocarcinomas
Cancer Res., February 1, 2008; 68(3): 759 - 766.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. A. Kazi and R. D. Koos
Estrogen-Induced Activation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor Expression, and Edema in the Uterus Are Mediated by the Phosphatidylinositol 3-Kinase/Akt Pathway
Endocrinology, May 1, 2007; 148(5): 2363 - 2374.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. Blanco-Aparicio, L. Perez-Gallego, B. Pequeno, J. F.M. Leal, O. Renner, and A. Carnero
Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer
Carcinogenesis, March 1, 2007; 28(3): 584 - 594.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Sanchez, K. Sauve, N. Picard, and A. Tremblay
The Hormonal Response of Estrogen Receptor beta Is Decreased by the Phosphatidylinositol 3-Kinase/Akt Pathway via a Phosphorylation-dependent Release of CREB-binding Protein
J. Biol. Chem., February 16, 2007; 282(7): 4830 - 4840.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Yeager, A. Klein-Szanto, S. Kimura, and A. Di Cristofano
Pten Loss in the Mouse Thyroid Causes Goiter and Follicular Adenomas: Insights into Thyroid Function and Cowden Disease Pathogenesis
Cancer Res., February 1, 2007; 67(3): 959 - 966.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.